ADCT vs. PAHC, WVE, ELVN, VERV, NTLA, COLL, AKBA, SYRE, MLYS, and AVDL
Should you be buying ADC Therapeutics stock or one of its competitors? The main competitors of ADC Therapeutics include Phibro Animal Health (PAHC), WAVE Life Sciences (WVE), Enliven Therapeutics (ELVN), Verve Therapeutics (VERV), Intellia Therapeutics (NTLA), Collegium Pharmaceutical (COLL), Akebia Therapeutics (AKBA), Spyre Therapeutics (SYRE), Mineralys Therapeutics (MLYS), and Avadel Pharmaceuticals (AVDL). These companies are all part of the "pharmaceutical products" industry.
ADC Therapeutics vs. Its Competitors
Phibro Animal Health (NASDAQ:PAHC) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.
Phibro Animal Health has higher revenue and earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.
Phibro Animal Health currently has a consensus target price of $21.80, indicating a potential downside of 22.12%. ADC Therapeutics has a consensus target price of $7.75, indicating a potential upside of 177.78%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe ADC Therapeutics is more favorable than Phibro Animal Health.
99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by insiders. Comparatively, 5.4% of ADC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Phibro Animal Health had 5 more articles in the media than ADC Therapeutics. MarketBeat recorded 6 mentions for Phibro Animal Health and 1 mentions for ADC Therapeutics. Phibro Animal Health's average media sentiment score of 0.33 beat ADC Therapeutics' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the media.
Phibro Animal Health has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500.
Phibro Animal Health has a net margin of 2.68% compared to ADC Therapeutics' net margin of -197.64%. Phibro Animal Health's return on equity of 30.51% beat ADC Therapeutics' return on equity.
Summary
Phibro Animal Health beats ADC Therapeutics on 11 of the 16 factors compared between the two stocks.
Get ADC Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ADCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ADC Therapeutics Competitors List
Related Companies and Tools
This page (NYSE:ADCT) was last updated on 7/3/2025 by MarketBeat.com Staff
